Molecular aspects of brain metastases in breast cancer

Tomasik, Bartłomiej; Bieńkowski, Michał; Górska, Zuzanna; Gutowska, Klaudia; Kumięga, Paulina; Jassem, Jacek; Duchnowska, Renata

doi:10.1016/j.ctrv.2023.102521

Cited by 8 publications

(3 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As highlighted by the authors, the risk and prognosis vary depending on the BC subtype. According to existing literature, patients who are HER2-positive and those with triple-negative BC, exhibit higher rates of brain metastases, approximately 20%-50% and 25%-46% respectively, will eventually develop brain metastasis[ 6 ].…”

Section: To the Editormentioning

confidence: 99%

Bridging the gap: Predicting brain metastasis in breast cancer

Gonsalves,

Ciérvide,

Couñago

2024

World J Clin Oncol

View full text Add to dashboard Cite

Chen et al explored clinicopathological features and prognostic factors, revealing advanced tumor stage, lung metastases, HER-2 overexpression, and triple-negative status as key contributors. Recent research connects astrocytes' role in brain metastasis with signaling pathways and the impact of Trastuzumab on HER-2 tumor survival. Factors such as positive HER2 status, lack of estrogen receptor expression, and liver metastasis are identified as additional risk factors. The routine use of magnetic resonance imaging, insights into gene mutations associated with metastasis, and the role of radiotherapy, including prophylaxis possibilities, is controversial in clinical practice. Understanding these risk factors in a multidisciplinary collaboration is precise for local treatments and targeted therapies, particularly for HER2+ tumors, impacting directly on longer survival.

show abstract

Section: To the Editormentioning

confidence: 99%

Bridging the gap: Predicting brain metastasis in breast cancer

Gonsalves,

Ciérvide,

Couñago

2024

World J Clin Oncol

View full text Add to dashboard Cite

show abstract

“… 1 Despite the overall progress in cancer treatment, options for managing metastatic cancers, particularly brain metastases, remain constrained. 2 , 3 , 4 The distinct characteristics of the brain, including the blood–brain barrier (BBB), intricate microenvironment, and immune privilege, all pose significant obstacles to devising treatments for cancer cells that metastasize to the brain. Developing innovative strategies that significantly enhance therapeutic efficacy in the context of metastatic brain tumors remains the “holy grail” of cancer research.…”

Section: Introductionmentioning

confidence: 99%

Experimental models for cancer brain metastasis

Liu,

Dong,

Liu

et al. 2024

Cancer Pathogenesis and Therapy

View full text Add to dashboard Cite

“…For this reason, the cells must determine the modification of the brain extracellular matrix (ECM) to facilitate their passage and creating metastatic foci ( 9 ). As with other metastatic sites, the development of BMs from BC is a multi-step process with a cascade mechanism ( 10 ). We present this article in accordance with the Narrative Review reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1126/rc ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives

Passalacqua,

Ciappina,

Di Pietro

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background and Objective Brain metastases (BMs) are present in approximately 55% of patients with HER2-positive breast cancer (HER2+ BC). The introduction of anti-HER2 agents has radically changed the prognosis of these patients by prolonging overall survival. Methods In this review, we describe the biology of central nervous system (CNS) spreading in patients with HER2+ BC. We also provide a literature review of current treatment strategies of brain metastatic BC, focusing on HER2+ disease, and future perspectives. Key Content and Findings Treatment of symptomatic BMs includes traditionally neurosurgery and/or radiotherapy, depending on the number of metastases, performance status and systemic disease control. Local treatments, such as surgical excision of BM and stereotactic radiosurgery (SRS), when feasible, are preferred over whole-brain radiotherapy, because of related cognitive impairment. These treatments can lead to a local control of the disease, however, systemic relapses can affect the prognosis of these patients. Recently, new anti-HER2 agents have demonstrated to be effective on BMs, thereby leading to improved survival outcomes with an acceptable quality of life. Despite the clinical benefit of these approaches, BMs still represent a cause of death and effective therapeutic strategies are needed. Conclusions Different targeted agents have demonstrated significant efficacy with tolerable safety profiles in HER2+ BC patients with BM, and have already been approved for clinical use in this setting. A better understanding of the molecular mechanisms underlying the onset of BMs could suggest novel targeted approaches in order to prevent CNS localization or delay progression to CNS in HER-2 metastatic patients.

show abstract

Molecular aspects of brain metastases in breast cancer

Cited by 8 publications

References 154 publications

Bridging the gap: Predicting brain metastasis in breast cancer

Bridging the gap: Predicting brain metastasis in breast cancer

Experimental models for cancer brain metastasis

Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives

Contact Info

Product

Resources

About